Zhang Ruoyu, Kofidis Theo, Kamiya Hiroyuki, Shrestha Malakh, Tessmann Rene, Haverich Axel, Klima Uwe
Division of Thoracic- and Cardiovascular Surgery, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany.
Eur J Cardiothorac Surg. 2006 Oct;30(4):617-20. doi: 10.1016/j.ejcts.2006.07.016. Epub 2006 Aug 28.
Extracorporeal membrane oxygenation (ECMO) has been used as initial, biventricular circulatory support for patients with severe postcardiotomy cardiogenic shock (PCS). Due to its aggressiveness and limited weaning quote, concerns have been raised about maintenance of ECMO support regarding duration. However, it is frequently hazardous for physicians to make an individualized decision, whether and when discontinuation of ECMO support should be considered. We tried to find measurable values during ECMO support that could predict the patient mortality on ECMO support.
During a 9-year period, 32 patients (mean age 55.4+/-11.9; ranging from 30 to 75 years) with ECMO support for postcardiotomy cardiogenic shock were included in this study.
Eighteen patients died without weaning (group I, 56.25%), while 14 patients could be weaned off the ECMO support (group II, 43.75%). In the group II, six patients (18.75%) died later in the postoperative course and eight patients (25%) survived to be discharged from hospital. The overall survival of all 32 patients at 30 days was 31.25% (n=10). At a follow-up period of 3.88+/-1.58 years, the overall survival rate was 12.5% (n=4). Mean duration of ECMO support was 2.7+/-1.7 days. The following variables were significantly different between the two groups: blood lactate level and the level of MB isoenzyme of creatine kinase (CK-MB) 48 h after ECMO initiation (p<0.01, p=0.001) as well as the CK-MB relative index as the ratio of CK-MB to total CK (p<0.001). Logistic regression identified that only the CK-MB relative index 48 h after ECMO initiation was associated with mortality on ECMO support (p=0.011, odds ratio=1.219, 95% confidence interval: 1.046-1.421).
For adult non-transplantation patients with postcardiotomy cardiogenic shock, the CK-MB relative index 48 h after ECMO initiation can be a predictor of mortality on ECMO support. This might be a useful tool for considering a patient either for discontinuation of ECMO support or further treatment.
体外膜肺氧合(ECMO)已被用作心脏术后严重心源性休克(PCS)患者的初始双心室循环支持。由于其激进性和脱机成功率有限,人们对ECMO支持的持续时间提出了担忧。然而,对于医生来说,决定是否以及何时应考虑停止ECMO支持往往具有风险。我们试图找出ECMO支持期间可预测患者在ECMO支持下死亡率的可测量值。
在9年期间,本研究纳入了32例接受ECMO支持治疗心脏术后心源性休克的患者(平均年龄55.4±11.9岁;年龄范围为30至75岁)。
18例患者未脱机死亡(I组,56.25%),而14例患者成功脱机(II组,43.75%)。在II组中,6例患者(18.75%)在术后晚期死亡,8例患者(25%)存活出院。32例患者30天的总生存率为31.25%(n = 10)。在3.88±1.58年的随访期内,总生存率为12.5%(n = 4)。ECMO支持的平均持续时间为2.7±1.7天。两组之间以下变量存在显著差异:ECMO启动后48小时的血乳酸水平和肌酸激酶MB同工酶(CK-MB)水平(p<0.01,p = 0.001)以及CK-MB相对指数(CK-MB与总CK的比值)(p<0.001)。逻辑回归分析表明,仅ECMO启动后48小时的CK-MB相对指数与ECMO支持下的死亡率相关(p = 0.011,比值比 = 1.219,95%置信区间:1.046 - 1.421)。
对于心脏术后心源性休克的成年非移植患者,ECMO启动后48小时的CK-MB相对指数可作为ECMO支持下死亡率的预测指标。这可能是考虑患者是否停止ECMO支持或进一步治疗的有用工具。